OMERS ADMINISTRATION Corp Purchases 606 Shares of Johnson & Johnson (NYSE:JNJ)

OMERS ADMINISTRATION Corp boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 205,728 shares of the company’s stock after purchasing an additional 606 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Johnson & Johnson were worth $29,752,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $453,000. Oregon Pacific Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth about $949,000. Horan Securities Inc. raised its stake in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after purchasing an additional 90 shares during the period. Strategic Financial Concepts LLC grew its holdings in Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after buying an additional 1,271 shares in the last quarter. Finally, KPP Advisory Services LLC raised its holdings in Johnson & Johnson by 4.7% during the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after buying an additional 515 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Leerink Partners lowered their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $171.82.

Johnson & Johnson Stock Down 0.2%

Shares of JNJ opened at $153.88 on Tuesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50 day simple moving average of $157.67 and a two-hundred day simple moving average of $154.18. The company has a market cap of $370.24 billion, a P/E ratio of 23.14, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.